ID

42817

Beschreibung

Ropinirole Case Report Form GSK RRL100013 GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Stichworte

  1. 22.02.18 22.02.18 -
  2. 24.02.18 24.02.18 -
  3. 25.02.18 25.02.18 -
  4. 17.09.21 17.09.21 -
Rechteinhaber

gsk

Hochgeladen am

17. September 2021

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Ropinirole Case Report Form GSK RRL100013

SERIOUS ADVERSE EVENT

SERIOUS ADVERSE EVENT
Beschreibung

SERIOUS ADVERSE EVENT

DEFINITION OF A SERIOUS ADVERSE EVENT
Beschreibung

Diagnosis Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. Start Date Record the start date of the first occurrence of the SAE. Start Time Record the start time of the SAE. Outc o m e All SAEs must b e followed until the events are resolved, t h e condition stabilises, the events are otherwise explained, or the subject i s lost to follow-up. Indicate if the event was 'Recovered/Resolved' or 'Recovered/Resolved with sequelae'. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as 'Not recovered/Not resolved' or 'Recovering/Resolving'. Also enter 'Not recovered/Not resolved' if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death. End Date Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ End Time Resolved with sequelae, enter the date the subject's medical condition resolved or stabilised. Leave blank if the SAE is 'Not recovered/Not resolved' or 'Recovering/Resolving'. Record the end time of the SAE. Maximum Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Intensity Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = Those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma). Action Taken with lnvestigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. lnvestigational Dose reduced = Dose is reduced for one or more investigational product(s). Product(s) as a Result of the SAE Dose increased = Dose increased for one or more investigational product(s). Dose not changed = lnvestigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s). Withdrawal Indicate 'Yes' if the event(s) were directly respons ble for the subject's withdrawal as indicated on the Study Conclusion page, otherwise indicate 'No'. Relationship to It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be lnvestigational reviewed on receipt of any new information and amended if necessary. 'A reasonable poss bility' is meant to convey that there are facts/evidence or arguments Product(s) to suggest a causal relationship. Facts/evidence or arguments that may support 'a reasonable possibility' include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallen

Datentyp

text

Alias
UMLS CUI [1]
C1519255
INSTRUCTIONS FOR COMPLETING SERIOUS ADVERSE EVENTS
Beschreibung

Diagnosis Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. Start Date Record the start date of the first occurrence of the SAE. Start Time Record the start time of the SAE. Outc o m e All SAEs must b e followed until the events are resolved, t h e condition stabilises, the events are otherwise explained, or the subject i s lost to follow-up. Indicate if the event was 'Recovered/Resolved' or 'Recovered/Resolved with sequelae'. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as 'Not recovered/Not resolved' or 'Recovering/Resolving'. Also enter 'Not recovered/Not resolved' if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death. End Date Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ End Time Resolved with sequelae, enter the date the subject's medical condition resolved or stabilised. Leave blank if the SAE is 'Not recovered/Not resolved' or 'Recovering/Resolving'. Record the end time of the SAE. Maximum Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Intensity Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = Those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma). Action Taken with lnvestigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. lnvestigational Dose reduced = Dose is reduced for one or more investigational product(s). Product(s) as a Result of the SAE Dose increased = Dose increased for one or more investigational product(s). Dose not changed = lnvestigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s). Withdrawal Indicate 'Yes' if the event(s) were directly respons ble for the subject's withdrawal as indicated on the Study Conclusion page, otherwise indicate 'No'. Relationship to It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be lnvestigational reviewed on receipt of any new information and amended if necessary. 'A reasonable poss bility' is meant to convey that there are facts/evidence or arguments Product(s) to suggest a causal relationship. Facts/evidence or arguments that may support 'a reasonable possibility' include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallen

Datentyp

text

SERIOUS ADVERSE EVENTS
Beschreibung

SERIOUS ADVERSE EVENTS

SERIOUS ADVERSE EVENTS
Beschreibung

SERIOUS ADVERSE EVENTS

Datentyp

text

Alias
UMLS CUI [1]
C1519255
Start Date
Beschreibung

Start Date

Datentyp

date

Alias
UMLS CUI [1]
C0808070
Start Time
Beschreibung

Start Time

Datentyp

time

Alias
UMLS CUI [1]
C1301880
Outcome
Beschreibung

Outcome

Datentyp

text

Alias
UMLS CUI [1]
C1705586
End Date
Beschreibung

End Date

Datentyp

text

Alias
UMLS CUI [1]
C0806020
End time
Beschreibung

End time

Datentyp

time

Alias
UMLS CUI [1]
C1522314
Maximum Intensity
Beschreibung

Maximum Intensity

Datentyp

text

Alias
UMLS CUI [1]
C1710066
Action Taken with Investigational Product(s) as a Result of the Serious AE
Beschreibung

Action Taken with Investigational Product(s) as a Result of the Serious AE

Datentyp

text

Alias
UMLS CUI [1,1]
C1704758
UMLS CUI [1,2]
C1519255
Withdrawal
Beschreibung

Withdrawal

Datentyp

text

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C1519255
Relationship to lnvestigational Product(s)
Beschreibung

Relationship to lnvestigational Product(s)

Datentyp

text

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C1522508
Did the subject experience any serious adverse events during the study?
Beschreibung

Did the subject experience any serious adverse events during the study?

Datentyp

boolean

Alias
UMLS CUI [1]
C1519255

Ähnliche Modelle

SERIOUS ADVERSE EVENT

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
SERIOUS ADVERSE EVENT
DEFINITION OF A SERIOUS ADVERSE EVENT
Item
DEFINITION OF A SERIOUS ADVERSE EVENT
text
C1519255 (UMLS CUI [1])
Item
INSTRUCTIONS FOR COMPLETING SERIOUS ADVERSE EVENTS
text
Code List
INSTRUCTIONS FOR COMPLETING SERIOUS ADVERSE EVENTS
CL Item
Diagnosis (Diagnosis)
C0011900 (UMLS CUI-1)
(Comment:en)
CL Item
Start Date (Start Date)
C0808070 (UMLS CUI-1)
(Comment:en)
CL Item
Start Time (Start Time)
C1301880 (UMLS CUI-1)
(Comment:en)
CL Item
Outcome (Outcome)
C1705586 (UMLS CUI-1)
(Comment:en)
CL Item
End Date (End Date)
C0806020 (UMLS CUI-1)
(Comment:en)
CL Item
End Time (End Time)
C1522314 (UMLS CUI-1)
(Comment:en)
CL Item
Maximum Intensity (Maximum Intensity)
C1710066 (UMLS CUI-1)
(Comment:en)
CL Item
Withdrawal (Withdrawal)
C2349954 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
(Comment:en)
Item Group
SERIOUS ADVERSE EVENTS
SERIOUS ADVERSE EVENTS
Item
SERIOUS ADVERSE EVENTS
text
C1519255 (UMLS CUI [1])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Start Time
Item
Start Time
time
C1301880 (UMLS CUI [1])
Outcome
Item
Outcome
text
C1705586 (UMLS CUI [1])
End Date
Item
End Date
text
C0806020 (UMLS CUI [1])
End time
Item
End time
time
C1522314 (UMLS CUI [1])
Maximum Intensity
Item
Maximum Intensity
text
C1710066 (UMLS CUI [1])
Action Taken with Investigational Product(s) as a Result of the Serious AE
Item
Action Taken with Investigational Product(s) as a Result of the Serious AE
text
C1704758 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Withdrawal
Item
Withdrawal
text
C2349954 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Relationship to lnvestigational Product(s)
Item
Relationship to lnvestigational Product(s)
text
C0304229 (UMLS CUI [1,1])
C1522508 (UMLS CUI [1,2])
Did the subject experience any serious adverse events during the study?
Item
Did the subject experience any serious adverse events during the study?
boolean
C1519255 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video